Oncotype IQ Products
Oncotype IQ
Actionable genomic intelligence to inform cancer treatment decisions across the patient journey

Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smarter at every stage, our Oncotype IQ diagnostic tests and services portfolio delivers clinically relevant genomic intelligence that reveals the individual biology of a patient's tumor. This additional genomic insight helps physicians optimize treatment decisions for breast, colon, prostate and lung cancers.

Currently, the Oncotype IQ portfolio consists of Oncotype SEQ, a liquid biopsy tumor mutation panel, and Oncotype DX, our flagship line of gene expression tests, which have been used to guide treatment decisions for more than 700,000 cancer patients worldwide.

Moving forward, our portfolio of tests and services is expanding. We intend our ongoing product development programs to broaden our Oncotype IQ offerings to include tissue and liquid-based tests throughout the patient cancer care continuum, and an easily accessed, web-based information platform to gather and help evaluate patient test results over time.

Oncotype DX: Defining Treatment Options and Personalizing Decisions

The Oncotype DX diagnostic tests analyze the activity of selected sets of genes in a patient’s tumor tissue sample, in order to gain personalized biological information to optimize treatment decisions for breast, prostate and colon cancer patients. 
~//-/media/ODX-SEQ/Oncotype_SEQ_LS_RGB_M01.ashx

Oncotype SEQ Liquid Select

As a clinically actionable blood-based panel, Oncotype SEQ uses next-generation sequencing to identify select actionable genomic alterations for the treatment of patients with late-stage cancer.

Our Product Pipeline

Genomic Health has plans to develop new diagnostic tests for tumor typing and tumor tracking that address critical treatment questions throughout each of the many stages of cancer.
My Colon Cancer Coach